MP22-03 DUAL-SPECIFICITY TYROSINE PHOSPHORYLATION-REGULATED KINASE 2 AS A NOVEL MARKER IN BLADDER CANCER PATIENTS RECEIVING NEOADJUVANT CHEMOTHERAPY

You have accessJournal of UrologyBladder Cancer: Detection & Screening1 Apr 2014MP22-03 DUAL-SPECIFICITY TYROSINE PHOSPHORYLATION-REGULATED KINASE 2 AS A NOVEL MARKER IN BLADDER CANCER PATIENTS RECEIVING NEOADJUVANT CHEMOTHERAPY Shunichiro Nomura, Yasutomo Suzuki, Jun Akatsuka, Ryo Takahashi, Mika Terasaki, Ryoji Kimata, Ichiro Matsuzawa, Tsutomu Hamasaki, Go Kimura, Akira Shimizu, and Yukihiro Kondo Shunichiro NomuraShunichiro Nomura More articles by this author , Yasutomo SuzukiYasutomo Suzuki More articles by this author , Jun AkatsukaJun Akatsuka More articles by this author , Ryo TakahashiRyo Takahashi More articles by this author , Mika TerasakiMika Terasaki More articles by this author , Ryoji KimataRyoji Kimata More articles by this author , Ichiro MatsuzawaIchiro Matsuzawa More articles by this author , Tsutomu HamasakiTsutomu Hamasaki More articles by this author , Go KimuraGo Kimura More articles by this author , Akira ShimizuAkira Shimizu More articles by this author , and Yukihiro KondoYukihiro Kondo More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.851AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Radical cystectomy has been widely performed to treat muscle-invasive bladder cancer. However, radical cystectomy only provides 5-year survival in about 50% of patients. To improve these unsatisfactory results, the use of peri-operative chemotherapy has been explored. In particular, benefits of neoadjuvant chemotherapy have been observed in several trials. However, neoadjuvant chemotherapy fails some patients. Patient selection should thus be optimized for neoadjuvant chemotherapy. According to some reports, dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) is associated with sensitivity to platinum-based chemotherapy. We therefore investigated associations between DYRK2 expression and efficacy of neoadjuvant chemotherapy for patients with T1 high-grade or T2 bladder cancer. METHODS The cohort under investigation comprised 44 patients who underwent neoadjuvant chemotherapy for cT1 high-grade or cT2N0M0 bladder cancer at our institution between October 2002 and February 2011. Immunohistochemical analysis was used to determine expression of DYRK2 in specimens of bladder cancer obtained by transurethral resection before chemotherapy. Relationships between DYRK2 expression and both response rates and survival in these patients were analyzed. RESULTS DYRK2 expression was positive in 21 of the 44 patients (47.7%) and negative in 23 (52.3%). Staining intensity of 0 or 1+ was considered DYRK2-negative, and 2+ or 3+ staining was considered DYRK2-positive. 20 of 21 DYRK2-positive cases had complete response to neoadjuvant chemotherapy, whereas 11 of 23 DYRK2-negative cases did not have complete response. Sensitivity and specificity were 62.5% and 91.7%, respectively (p = 0.0018). In addition, disease-specific survival rate was significantly higher for DYRK2-positive patients than for DYRK2-negative patients (p = 0.017). CONCLUSIONS The results indicate that DYRK2 might represent a new molecular marker for predicting the efficacy of neoadjuvant chemotherapy in T1 high-grade and T2 bladder cancer. © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e235 Advertisement Copyright & Permissions© 2014MetricsAuthor Information Shunichiro Nomura More articles by this author Yasutomo Suzuki More articles by this author Jun Akatsuka More articles by this author Ryo Takahashi More articles by this author Mika Terasaki More articles by this author Ryoji Kimata More articles by this author Ichiro Matsuzawa More articles by this author Tsutomu Hamasaki More articles by this author Go Kimura More articles by this author Akira Shimizu More articles by this author Yukihiro Kondo More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...